Clinical significance of HCV core region, to antiviral therapy and clinicopatological features.
| Project/Area Number |
21590866
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Okinaka Memorial Institute for Medical Research |
|---|
Principal Investigator |
AKUTA Norio 財団法人冲中記念成人病研究所, 研究員 (20469638)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 肝臓学 / HCV / Coreアミノ酸置換 / Peginterferon / Ribavirin / 肝発癌 / 脂質代謝 / NS5A-ISDR / 糖代謝 / インスリン抵抗性 / HOMA-IR |
|---|
| Research Abstract |
Clinical significance of HCV core region, to antiviral therapy and clinicopatological features, was investigated. Substitutions of amino acid 70 and 91 of HCV genotype 1b could predict the response to peginterferon/ribavirin combination therapy and new therapy with Telaprevir. Furthermore, those also affected clinical outcome, including hepatocarcinogenesis, glucose metabolism, and lipid metabolism.
|
Report
(4 results)
Research Products
(31 results)
-
-
[Journal Article] Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variati on Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy2012
Author(s)
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H
-
Journal Title
Intervirology
Volume: 55
Issue: 3
Pages: 231-41
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
